Side-by-side · Research reference
AdamaxvsCrystagen
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AAnimal-StrongHUMAN-REVIEWED20/47 cited
BAnimal-MechanisticHUMAN-REVIEWED12/40 cited
Adamax
ACTH(4-10) Analogue · Russian Nootropic
Intranasal · Research Use Only
Crystagen
Khavinson Bioregulator · Immune-Thymic
SQ · Protocol variable
01Mechanism of Action
Parameter
Adamax
Crystagen
Primary target
Melanocortin receptors (MC-Rs) in hippocampus and cortex
B-lymphocytes in splenic tissueСhervyakova 2014
Pathway
ACTH(4-10) fragment → MC-R binding → BDNF/trkB upregulation → neurotrophic signaling
B-cell activation → Immune modulation during agingСhervyakova 2014
Downstream effect
Increased hippocampal BDNF expression, trkB tyrosine phosphorylation, enhanced conditioned avoidance learning, circadian rhythm normalizationDolotov 2006Arushanian 2008
B-cell activation via apoptosis reduction; no observed increase in splenic cell renewalСhervyakova 2014
Feedback intact?
Non-endocrine — devoid of adrenal axis effectsvan 1978
Unknown — bioregulator mechanism not fully characterized
Origin
ACTH(4-10) fragment with modified amino acid sequence at positions 8, 9, 10Teter 2001
Synthetic Lys-Glu-Asp-Gly tetrapeptide — Khavinson bioregulator series
Antibody development
—
—
02Dosage Protocols
Parameter
Adamax
Crystagen
Animal dose (rat)
50 mcg/kg body weightDolotov 2006
Single intranasal application; produced maximal BDNF response.
—
Frequency
Single-dose or chronic administration protocols
Chronic dosing normalized circadian rhythms; single-dose produced acute BDNF elevation.
Unknown — bioregulator protocols variable
Human dose (exploratory)
Not established — limited human data
ACTH(4-10) and analogs dosed 30–60 mcg intranasally in early human studies.
—
Evidence basis
Animal (rodent, rabbit) studies; minimal human RCT data
Animal / mechanistic
Timing
Variable — chronic administration for circadian effects
—
Standard dose
—
Not standardized — variable protocols
Russian bioregulator literature does not specify unified human dosing.
Duration
—
Unknown — chronic administration presumed in animal models
Half-life
—
Not reported
04Side Effects & Safety
Parameter
Adamax
Crystagen
Cardiovascular effects
ACTH(4-10) fragments may have pressor and cardioaccelerator actions at high dosesGruber 1984
Effects attenuated by α/β-receptor antagonists; observed at 30–1000 nmol/kg IV in rats.
—
Behavioral suppression
Suppression of aggression, reduced orientation-cognition reactions in rabbitsTeter 2001
May reflect anxiolytic or stress-dampening profile.
—
Long-term safety
Unknown — chronic human safety data lacking
—
Published adverse events
—
None reported in available animal literature
Human safety data
—
Absent — no controlled human trials identified
Autoimmune considerations
—
Theoretical concern with B-cell modulators in predisposed individuals
Absolute Contraindications
Adamax
- ·Pregnancy and lactation (precautionary; no data)
- ·Active cardiovascular instability (due to potential pressor effects)
Crystagen
- ·Active autoimmune disease (theoretical)
Relative Contraindications
Adamax
- ·Hypertension (monitor BP if using higher doses)
- ·Renal impairment (natriuretic effects may alter electrolyte balance)
Crystagen
- ·Pregnancy / lactation (no data)
- ·Active B-cell malignancies
05Administration Protocol
Parameter
Adamax
Crystagen
1. Reconstitution (if lyophilised)
Add sterile water or bacteriostatic water to lyophilised vial per manufacturer guidance. Roll gently — do not shake. Ensure clarity before use.
Subcutaneous injection — presumed from bioregulator class convention. Specific anatomical sites not standardized.
2. Route
Intranasal administration is the primary route in animal and exploratory human studies. Delivered via nasal spray or dropper to ensure mucosal absorption.Dolotov 2006Smolnik 2000
Protocol not standardized. If lyophilized, sterile water or bacteriostatic saline typical for peptide bioregulators.
3. Timing
Variable. Single-dose protocols for acute cognitive tasks; chronic daily dosing for circadian rhythm normalization and sustained neuroprotection.
Not specified. Bioregulator protocols vary — some practitioners advocate evening dosing, others morning.
4. Storage
Lyophilised: room temperature, light-protected. Reconstituted: refrigerate 2–8 °C, use within manufacturer-specified timeframe.
Lyophilized: room temperature, light-protected. Reconstituted: refrigerate, use within days to weeks depending on preservative.
06Stack Synergy
Adamax
+ Semax
ModerateBoth Adamax and Semax are ACTH(4-10)-derived nootropics acting via melanocortin receptors and BDNF upregulation. Adamax has distinct amino acid modifications at positions 8-10, potentially offering complementary receptor binding profiles or metabolic stability. Stacking may amplify neurotrophic signaling and cognitive enhancement, though direct synergy studies are absent. Theoretical multi-pathway benefit.
- Adamax
- Research dose intranasal
- Semax
- 300–600 mcg intranasal
- Frequency
- Once daily, morning or pre-cognitive task
- Primary benefit
- Enhanced BDNF upregulation, cognitive performance, neuroprotection
Crystagen
+ Vilon
Multi-pathwayVilon (Lys-Glu) activates T-helper cells via apoptosis reduction, while Crystagen activates B-cells. Dual T/B immune modulation in aging models may provide complementary thymic-immune support within the Khavinson bioregulator framework. Both target splenic immune aging through distinct lymphocyte subsets.
- Crystagen
- Dose unknown · SQ
- Vilon
- Dose unknown · SQ
- Frequency
- Protocol variable
- Primary benefit
- Broader thymic-immune coverage (T-cell + B-cell)